Stevenage Bioscience Catalyst Incubator Building G
About KaNDy TherapeuticsKaNDy Therapeutics was spun out from NeRRe Therapeutics in 2017, and at the same time, all formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 was transferred to KaNDy Therapeutics.
Founder, CSO, and COO: Mike Trower
CMO: Steve Pawsey
Currently, there are no jobs for this employer on BioSpace.
Browse jobs with BioSpace Featured Employers here.